The venom of the Eastern coral snake Micrurus fulvius can cause respiratory paralysis in the bitten patient, which is attributable to -neurotoxins (-NTx). The aim of this work was to study the biodistribution and lymphatic tracking by molecular imaging of the main -NTx of M. fulvius venom. -NTx was bioconjugated with the chelator diethylenetriaminepenta-acetic acid (DTPA) and radiolabeled with the radionuclide Gallium-67. Radiolabeling efficiency was 60%-78%; radiochemical purity 92%; and stability at 48 h 85%. The median lethal dose (LD50) and PLA(2) activity of bioconjugated -NTx decreased 3 and 2.5 times, respectively, in comparison with native -NTx. The immune recognition by polyclonal antibodies decreased 10 times. Biodistribution of -NTx-DTPA-Ga-67 in rats showed increased uptake in popliteal, lumbar nodes and kidneys that was not observed with Ga-67-free. Accumulation in organs at 24 h was less than 1%, except for kidneys, where the average was 3.7%. The inoculation site works as a depot, since 10% of the initial dose of -NTx-DTPA-Ga-67 remains there for up to 48 h. This work clearly demonstrates the lymphatic system participation in the biodistribution of -NTx-DTPA-Ga-67. Our approach could be applied to analyze the role of the lymphatic system in snakebite for a better understanding of envenoming.

$EVWUDFW Application of radionuclides due to their unique nature is still attracting the interest of professionals from different branches of science. In this thesis, the unifying topic is the utilization of various radioactive labels on polymeric carriers for biomedicinal purposes. In the introductory part, the area of use of the investigated substances - in terms of their possible application in nuclear medicine, is presented to the reader. The experimental work is divided into three main sections dealing with synthesis and studying properties of appropriate selected polymers, their metal chelates and radiolabeling. First part of the study describes development of new strategies for labeling of polymeric carriers with radiometal cations and radioiodine, whereas in the following sections of the study synthesis and investigation of biocompatible polymer materials is discussed. New possible approaches in the diagnostics and therapy of cancer by using polymeric chelates as carriers are presented as well as the use of macroporous metal chelating polymer beads as potential therapeutics intended for radioembolization of liver malignancies and for the therapy of Wilson's disease. Investigated polymers have been shown to be non-toxic, to have good in vitro stability and to have the ability to be radiolabeled in...

Thesis (Ph.D)--Biomedical Engineering, Georgia Institute of Technology, 2009. / Committee Chair: Gang Bao; Committee Member: Kurt D. Pennell; Committee Member: Mark M. Goodman; Committee Member: Xiaoping P. Hu; Committee Member: Yadong Wang. Part of the SMARTech Electronic Thesis and Dissertation Collection.

PURPOSE. To determine the intravitreal pharmacokinetic properties and to study the systemic biodistribution characteristics of 1-124-labeled bevacizumab, ranibizumab, and aflibercept with positron emission tomography-computed tomography (PET/CT) imaging in a nonhuman primate model. METHODS. Three groups with four owl monkeys per group underwent intravitreal injection with 1.25 mg/0.05 mL 1-124 bevacizumab, 0.5 mg/0.05 mL 1-124 ranibizumab, or 2.0 mg/0.05 mL 1-124 aflibercept in the right eye of each subject. All subjects were imaged using PET/CT on days 0, 1, 2, 4, 8, 14, 21, 28, and 35. Serum blood draws were performed at hours 1, 2, 4, 8, 12 and days 1, 2, 4, 8, 14, 21, 28, and 35. Radioactivity emission measurements were used to determine the intravitreal half-lives of each agent and to study the differences of radioactivity uptake in nonocular organs. RESULTS. The intravitreal half-lives were 3.60 days for 1-124 bevacizumab, 2.73 days for 1-124 ranibizumab, and 2.44 days for 1-124 aflibercept. Serum levels were highest and most prolonged for bevacizumab as compared to both ranibizumab and aflibercept. All agents were primarily excreted through the renal and mononuclear phagocyte systems. However, bevacizumab was also found in significantly higher levels in the liver, heart, and distal femur bones. CONCLUSIONS. Among the three anti-VEGF agents used in clinical practice, bevacizumab demonstrated the longest intravitreal retention time and aflibercept the shortest. Significantly higher and prolonged levels of bevacizumab were found in the serum as well as in the heart, liver, and distal bones. These differences may be considered by clinicians when formulating treatment algorithms for intravitreal therapies with these agents.

Methotrexate (MTX), as a pharmaceutical, is frequently used in tumor chemotherapy and is also a part of the established treatment of a number of autoimmune inflammatory disorders. Radiolabeled MTX has been studied as a tumor-diagnostic agent in a number of published studies. In the present study, the potential use of technetium-99m-labelled MTX (Tc-99m-MTX) as a radiotracer was investigated for the identification of inflammatory target sites. The labelling of MTX was carried out via a Tc-99m-gluconate precursor. Evaluation studies included in vitro stability, plasma protein binding assessment, partition-coefficient estimation, in vivo scintigraphic imaging and ex vivo animal experiments in an animal inflammation model. MTX was successfully labelled with Tc-99m, with a radiochemical purity of >95%. Stability was assessed in plasma, where it remained intact up to 85% at 4 h post-incubation, while protein binding of the radiotracer was observed to be similar to 50% at 4 h. These preclinical ex vivo and in vivo studies indicated that Tc-99m-MTX accumulates in inflamed tissue, as well as in the spinal cord, joints and bones; all areas with relatively high remodeling activity. The results are promising, and set the stage for further work on the development and application of Tc-99m-MTX as a radiotracer for inflammation associated with rheumatoid arthritis.

Têm sido estudadas novas modalidades para o diagnóstico e tratamento de câncer de próstata avançado baseado em peptídeos. Receptores para o peptídeo liberador de gastrina (GRPr) são superexpressos em vários tipos de células cancerígenas, incluindo câncer de mama e próstata. A bombesina é um análogo do peptídeo GRP de mamíferos que se liga com alta especificidade e afinidade a GRPr. Várias pesquisas têm sido realizadas para desenvolver e radiomarcar um análogo da bombesina com lutécio-177 com interesse para terapia de tumores pequenos ou metástases, devido às características físicas e viabilidade comercial do radionuclídeo. O objetivo deste trabalho foi estudar o processo de marcação e controle de qualidade de derivados da bombesina, usando como agente quelante DTPA e DOTA e espaçador aminoacídico Gly5, e realizar estudos de estabilidade e de biodistribuição de modo a avaliar o potencial de aplicação em estudos clínicos. Os estudos demonstraram que os análogos da bombesina estudados podem ser marcados com 177Lu com alto rendimento de marcação e alta atividade específica. Os estudos de estabilidade in vitro sugerem que os derivados DOTA-conjugados apresentam maior estabilidade que o DTPA-conjugados quando armazenados sob refrigeração e em soro humano. O coeficiente de partição do PG5N-DOTA-177Lu indicou maior lipofilicidade quando comparado com o derivado PG5M-DOTA-177Lu , porém sem influência sobre o clareamento sanguíneo ou captação hepática do composto. Os compostos DOTA-conjugados apresentam menor ligação às proteínas plasmáticas, corroborado pelo rápido clareamento sanguíneo observado nos estudos in vivo. Os estudos de biodistribuição com os compostos PG5M-DOTA-177Lu e PG5N-DOTA-177Lu mostraram o rápido clareamento sanguíneo dos compostos e excreção renal, e baixa captação óssea, indicando estabilidade in vivo dos derivados 177Lu-DOTA. O composto PG5M-DOTA-177Lu apresentou maior captação no pâncreas e intestinos, órgãos com maior porcentagem de receptores para bombesina. Entretanto, a ligação dos compostos às células tumorais (PC-3) in vitro foi similar para ambos os compostos. / New therapy modalities for the treatment of advanced prostate cancer based on peptide analogues are reviewed. It has been shown that gastrin releasing peptide receptors (GRPr) are overexpressed in various types of cancer cells including prostate and breast cancer. Bombesin is an analogue of the mammalian GRP that binds with high specificity and affinity to GRPr. Significant research efforts have been devoted to the design bombesin analogues labeled with 177Lu considering the excellent radiophysical properties and commercial availability of the radionuclide. The aim of this work was to study the labeling and the quality control of a bombesin analogues with Lu-177 using DOTA and DTPA as chelate group and an aminoacidic spacers Gly5 and study the stability and biodistribution properties in order to evaluate the potencial for clinical application. The studies showed that the bombesin analogs were labeled with 177Lu with high radiochemical yield and high specific activity. In vitro stability studies showed that DOTA-conjugated peptides were more stable than DTPA-conjugated, when stored under refrigeration or in human serum. The partition coefficient values showed that 177LuDOTA-PG5N was more lipophilic when compared with 177LuDOTA-PG5M but without influence on blood clearance and liver uptake. The DOTA-conjugated peptides presented low binding to plasma proteins, that contributes for fast blood clearance in vivo. Biodistribution studies of 177LuDOTA-PG5M and 177LuDOTA-PG5N, showed significant renal uptake, as a result of the urinary excretion and low bone uptake, that indicated the in vivo stability of the 177Lu-DOTA-complexes. The compound 177LuDOTA-PG5M showed higher uptake on pancreas and intestinses and these organs presents high density of BBN receptors. But the in vitro binding assays (PC-3 tumors cells) showed similar results for both compounds.

Têm sido estudadas novas modalidades para o diagnóstico e tratamento de câncer de próstata avançado baseado em peptídeos. Receptores para o peptídeo liberador de gastrina (GRPr) são superexpressos em vários tipos de células cancerígenas, incluindo câncer de mama e próstata. A bombesina é um análogo do peptídeo GRP de mamíferos que se liga com alta especificidade e afinidade a GRPr. Várias pesquisas têm sido realizadas para desenvolver e radiomarcar um análogo da bombesina com lutécio-177 com interesse para terapia de tumores pequenos ou metástases, devido às características físicas e viabilidade comercial do radionuclídeo. O objetivo deste trabalho foi estudar o processo de marcação e controle de qualidade de derivados da bombesina, usando como agente quelante DTPA e DOTA e espaçador aminoacídico Gly5, e realizar estudos de estabilidade e de biodistribuição de modo a avaliar o potencial de aplicação em estudos clínicos. Os estudos demonstraram que os análogos da bombesina estudados podem ser marcados com 177Lu com alto rendimento de marcação e alta atividade específica. Os estudos de estabilidade in vitro sugerem que os derivados DOTA-conjugados apresentam maior estabilidade que o DTPA-conjugados quando armazenados sob refrigeração e em soro humano. O coeficiente de partição do PG5N-DOTA-177Lu indicou maior lipofilicidade quando comparado com o derivado PG5M-DOTA-177Lu , porém sem influência sobre o clareamento sanguíneo ou captação hepática do composto. Os compostos DOTA-conjugados apresentam menor ligação às proteínas plasmáticas, corroborado pelo rápido clareamento sanguíneo observado nos estudos in vivo. Os estudos de biodistribuição com os compostos PG5M-DOTA-177Lu e PG5N-DOTA-177Lu mostraram o rápido clareamento sanguíneo dos compostos e excreção renal, e baixa captação óssea, indicando estabilidade in vivo dos derivados 177Lu-DOTA. O composto PG5M-DOTA-177Lu apresentou maior captação no pâncreas e intestinos, órgãos com maior porcentagem de receptores para bombesina. Entretanto, a ligação dos compostos às células tumorais (PC-3) in vitro foi similar para ambos os compostos. / New therapy modalities for the treatment of advanced prostate cancer based on peptide analogues are reviewed. It has been shown that gastrin releasing peptide receptors (GRPr) are overexpressed in various types of cancer cells including prostate and breast cancer. Bombesin is an analogue of the mammalian GRP that binds with high specificity and affinity to GRPr. Significant research efforts have been devoted to the design bombesin analogues labeled with 177Lu considering the excellent radiophysical properties and commercial availability of the radionuclide. The aim of this work was to study the labeling and the quality control of a bombesin analogues with Lu-177 using DOTA and DTPA as chelate group and an aminoacidic spacers Gly5 and study the stability and biodistribution properties in order to evaluate the potencial for clinical application. The studies showed that the bombesin analogs were labeled with 177Lu with high radiochemical yield and high specific activity. In vitro stability studies showed that DOTA-conjugated peptides were more stable than DTPA-conjugated, when stored under refrigeration or in human serum. The partition coefficient values showed that 177LuDOTA-PG5N was more lipophilic when compared with 177LuDOTA-PG5M but without influence on blood clearance and liver uptake. The DOTA-conjugated peptides presented low binding to plasma proteins, that contributes for fast blood clearance in vivo. Biodistribution studies of 177LuDOTA-PG5M and 177LuDOTA-PG5N, showed significant renal uptake, as a result of the urinary excretion and low bone uptake, that indicated the in vivo stability of the 177Lu-DOTA-complexes. The compound 177LuDOTA-PG5M showed higher uptake on pancreas and intestinses and these organs presents high density of BBN receptors. But the in vitro binding assays (PC-3 tumors cells) showed similar results for both compounds.

Affibody molecules have lately shown great potential as tools for in vivo molecular imaging. These small, 3-helical bundles, with their highly stable protein scaffold, are well suited for the often harsh conditions of radiolabeling. Their small size allows for rapid clearance from the blood circulation which permits the collection of images already within hours after injection. This thesis includes four papers aimed at engineering different variants of a HER2-binding Affibody molecule to enable effective  and  flexible  radiolabeling  and  enhancing  the  molecular  imaging  in  terms  of  imaging contrast and resolution. In paper I an Affibody molecule was engineered to function as a multifunctional platform for site-specific labeling with different nuclides for radionuclide imaging. This was done using only natural amino  acids,  thereby  allowing  for  both  synthetic  and  recombinant  production.  By  grafting  the amino acid sequence -GSECG to the C-terminal of our model-protein, a HER2-binding Affibody molecule, we enabled site specific labeling with both trivalent radiometals and with  99m Tc. Maleim-ide-DOTA was conjugated to the cysteine residue for labeling with  111 In, while the peptide sequence was able to chelate  99m Tc directly. This approach can also be used for site-specific labeling with other probes available for thiol-chemistry, and is applicable also to other protein scaffolds. In paper II we investigated the impact of size and affinity of radiolabeled Affibody molecules on tumor targeting and image contrast. Two HER2-targeting Affibody molecules, a two-helix (~5 kDa) and a three-helix (~7 kDa) counterpart, were synthetically produced, labeled with  111 In via chelation by  DOTA  and  directly  compared  in  terms  of  biodistribution  and  targeting  properties.  Results showed  that  the  smaller  variant  can  provide  higher  contrast  images,  at  the  cost  of  lower  tumor uptake,  in  high-expressing  HER2-tumors.  However,  neither  the  tumor  uptake  nor  the  contrast of the two-helix variant is sufficient to compete with the three-helix molecule in tumors with low expression of HER2. In paper III and IV we were aiming to find methods to improve the labeling of Affibody molecules with  18 F for PET imaging. Current methods are either complex, time-consuming or generate heavily lipophilic conjugates. This results in low yields of radiolabeled tracer, low specific activity left for imaging, undesirable biodistribution or a combination thereof. In paper III we demonstrate a swift and efficient 2-step, 1-pot method for labeling HER2-binding Affibody molecules by the formation of aluminum  18 F-fluoride (Al 18 F) and its chelation by NOTA, all in 30 min. The results show that the  18 F-NOTA-approach is a very promising method of labeling Affibody molecules with  18 F and further investigation of this scheme is highly motivated. In the last paper we pursued the possibility of decreasing the high kidney retention that is common among small radiotracers with residual-izing radiometabolites. In this work  18 F-4-fluorobenzaldehyde (FBA) was conjugated to a synthetic HER2-targeting Affibody molecule via oxime ligation. However, to avoid elevated liver retention, as seen in previous studies with this kind of label, a hydrophilic triglutamyl spacer between the aminooxy moiety and the N-terminal was introduced. A comparison of the two constructs (with and without the triglutamyl spacer) showed a clear reduction of retention in both kidney and liver in NMRI mice at 2 h p.i. when the spacer was included. In the light of these promising results, further studies including tumor-bearing mice, are in preparation. / <p>QC 20130203</p>

Fatty acyl-Coenzyme As are metabolites of lipid anabolism and catabolism. A method was developed for their quantitation in extracts of cultured mammalian cells using liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS). Palmitoyl-CoA (C16:0-CoA) is utilized for de novo sphingolipid biosynthesis catalyzed by serine palmitoyltransferase (SPT), which condenses palmitoyl-CoA and serine to form 3-ketosphinganine. After reduction to form sphinganine (Sa), dihydroceramide synthase (CerS) can N-acylate the Sa using a second fatty acyl-CoA molecule, forming dihydroceramide (DHCer). The CerS enzyme family utilizes different acyl chain lengths of fatty acyl-CoAs in an isoform-specific manner, resulting in DHCer with N-acyl chains ranging from C16 to C26 [and even longer] in mammalian tissues. DHCer is trans-4,5-desaturated to yield ceramide, which is further metabolized by the addition of moieties at the 1-O-position, forming sphingomyelin (SM) and ceramide monohexose (CMH). The rates of fatty acyl-CoA and sphingolipid biosynthesis were determined using stable isotope-labeling and LC-ESI-MS/MS analysis of the analyte isotopologues and isotopomers. Isotopic labeling of palmitoyl-CoA with [U-13C]-palmitate in HEK293 and RAW264.7 cells was robust and rapid (~ 60% labeling of the metabolite pool in 3 hr). Isotopic labeling of sphingolipids indicated utilization of [M + 16]-palmitoyl-CoA by SPT and CerS isoforms in both cell types. Metabolic flux modeling was applied to the data for [U-13C]-palmitate activation to [M + 16]-palmitoyl-CoA and its subsequent utilization in de novo sphingolipid biosynthesis, and this analysis indicated rapid turn-over rates for palmitoyl-CoA and ceramide in both cell types. Palmitate treatment of cultured cells alters their metabolic status and gene expression, therefore labeling of palmitoyl-CoA by treatment with [1-13C]-acetate was employed. A distribution of mass-shifted palmitoyl-CoA species (isotopologues) is observed based on the number of incorporations of [1-13C]-acetate during de novo biosynthesis, requiring computational analysis to derive two parameters: the isotopic enrichment of the precursor pool, and the fraction of palmitoyl-CoA that was biosynthesized during the experiment. Previous reports by others describe mass isotopomer distribution analysis (MIDA) and isotopomer spectral analysis (ISA) for this purpose, and both calculation approaches indicated concurrent results. In summary, the quantitation of fatty acyl-CoAs and their isotopic enrichment during stable isotope-labeling studies of lipid metabolism can provide data that significantly change the interpretation of analyte quantitation in these experiments, as demonstrated here for investigations of de novo sphingolipid biosynthesis.

The purpose of this work was to develop methods to estimate the diffusion coefficient and elimination constant for dexamethasone in subcutaneous tissue. Solutions to the diffusion equation were found for different conditions relevant to implantation and injection. These solutions were then used as models for measured autoradiography data where the unknown model parameters were the diffusion coefficient and the elimination constant. The diffusion coefficient and elimination constant were then estimated by curve fitting the measured data to these models. Having these estimates would be of practical importance since inflammation surrounding implantable glucose sensors may be controlled through local release of dexamethasone at the site of implantation. Derivation of the appropriate model, how the model was used to estimate D and k, and various specific profile examples were investigated in detail. Osmotic pumps containing [3H]- dexamethasone were implanted into the subcutaneous tissue of rats. Digital autoradiography was used to measure the distribution of the [3H]-dexamethasone within the subcutaneous tissue at 6, 24, and 60 hours after implantation. Measured concentration profiles, near the catheter tip through which the agent was released, were compared to solutions of the diffusion equation in order to characterize drug diffusion coefficients and elimination constants. There was good agreement between the experimental data and the mathematical model used for estimation. The diffusion coefficient for dexamethasone in subcutaneous tissue was found to be D = 4.11+-1.77x10E-10 m2/s, and the elimination rate constant was found to be k = 3.65+-2.24x10E-5/s. Additionally, [3H]-dexamethasone was injected into the subcutaneous tissue of rats. Digital autoradiography was again used to measure the distribution of the [3H]- dexamethasone within the subcutaneous tissue at 2.5 and 20 minutes after injection. Measured concentration profiles were again compared to a mathematical model of drug diffusion for injection. There was good agreement between the experimental data and the mathematical model. The diffusion coefficient found using this simple injection method was 4.01+-2.01x10E-10 m2/s. The simple method given here for the determination of the diffusion coefficient is general enough to be applied to other substances and tissues as well.